Table 1.

Clinical scores and patient-related outcomes of Phase II and III dupilumab studies

Study	EASI	Pruritus (VAS) IGA	IGA	BSA	SCORAD	GISS	POEM	HADS	DLQI
Phase I–II
4 weeks monotherapy (day 29)43	EASI 50 in 59% dupilumab group versus 19% placebo EASI 75 in 29% dupilumab group versus 6% placebo Overall, −58% EASI dupilumab group versus −25% placebo	−41% dupilumab group −19% placebo	0 (clear) or 1 (almost clear) in 12% dupilumab group versus 6% placebo	−37% dupilumab group −15% placebo	N/A	N/A	N/A	N/A	N/A
12 weeks monotherapy (day 85)43	EASI 50 in 85% dupilumab group versus 35% placebo EASI 75 in 62% dupilumab group versus 15% placebo Overall, improvement in EASI of 74% in the dupilumab group versus 23% placebo	−56% dupilumab group −15% placebo	0 (clear) or 1 (almost clear) in 40% dupilumab group versus 7% placebo	−60% dupilumab group −18% placebo	N/A	N/A	N/A	N/A	N/A
4 weeks combination therapy (day 29)43	EASI 50 in 100% dupilumab group versus 50% placebo EASI 75 in 62% dupilumab group versus 40% placebo Overall, improvement in EASI of 76% in the dupilumab group versus 53% placebo	−71% dupilumab group −25% placebo	0 (clear) or 1 (almost clear) in 52% dupilumab group versus 30% placebo	−64% dupilumab group −37% placebo	N/A	N/A	N/A	N/A	N/A
Phase III
16 weeks monotherapy (day 112) – SOLO1 study (receiving dupilumab every week or every other week)48	EASI 75 in 52% weekly dupilumab group versus 51 every other week dupilumab group versus 15% placebo Overall, improvement in EASI of 72% in weekly dupilumab group versus 72% in every other week dupilumab group versus 38% placebo	≥4 points on numerical rating scale: in 40% of weekly dupilumab group versus 41% of every other week dupilumab group versus 12% placebo	0 or 1 (or reduction of ≥2 points from baseline) in 37% weekly dupilumab group versus 38% in every other week dupilumab group versus 10% placebo	−34% weekly dupilumab group versus −33% every other week dupilumab group versus 15% placebo	−57% weekly dupilumab group versus −58% every other week dupilumab group versus 29% placebo	−52% weekly dupilumab group versus −53% every other week dupilumab group versus 26% placebo	−11% weekly dupilumab group versus −12% every other week dupilumab group versus 5% placebo	−5% weekly dupilumab group versus −5% every other week dupilumab group versus 3% placebo	−9% weekly dupilumab group versus −9% every other week dupilumab group versus 5% placebo
16 weeks monotherapy (day 112) – SOLO2 study (receiving dupilumab every week or every other week)48	EASI 75 in 48% weekly dupilumab group versus 44 every other week dupilumab group versus 12% placebo Overall, improvement in EASI of 69% in weekly dupilumab group versus 67% in every other week dupilumab group versus 31% placebo	≥4 points on numerical rating scale: in 39% of weekly dupilumab group versus 36% of every other week dupilumab group versus 13% placebo	0 or 1 (or reduction of ≥2 points from baseline) in 36% weekly dupilumab group versus 36% in every other week dupilumab group versus 8% placebo	−32% weekly dupilumab group versus −31% every other week dupilumab group versus 13% placebo	−54% weekly dupilumab group versus −51% every other week dupilumab group versus 20% placebo	−47% weekly dupilumab group versus −46% every other week dupilumab group versus 18% placebo	−11% weekly dupilumab group versus −10% every other week dupilumab group versus 3% placebo	−6% weekly dupilumab group versus −5% every other week dupilumab group versus 1% placebo	−10% weekly dupilumab group versus −9% every other week dupilumab group versus 4% placebo

Abbreviations: EASI, Eczema Area and Severity Index; VAS, visual analog scale; IGA, Investigator’s Global Assessment; BSA, body surface area; SCORAD, SCORing Atopic Dermatitis; GISS, Global Individual Sign Score; POEM, Patient-Oriented Eczema Measure; HADS, Hospital Anxiety and Depression Scale; DLQI, Dermatology Life Quality Index; N/A, not applicable.